FACS assessment of HECA-452 and PSGL-1 expression on human T cells after bromelain treatment
| . | Cell staining (% positive [MCF]) . | |||
|---|---|---|---|---|
| CLA+ T cells . | CLAlow T cells . | |||
| Untreated . | Bromelain . | Untreated . | Bromelain . | |
| Anti-CLA (moAb HECA-452) | 99% (2304) | 68% (1869) | 18% (51) | 16% (48) |
| Anti–PSGL-1 (moAb PL-2) | 99% (97) | 1% (10) | 96% (105) | 0% (25) |
| . | Cell staining (% positive [MCF]) . | |||
|---|---|---|---|---|
| CLA+ T cells . | CLAlow T cells . | |||
| Untreated . | Bromelain . | Untreated . | Bromelain . | |
| Anti-CLA (moAb HECA-452) | 99% (2304) | 68% (1869) | 18% (51) | 16% (48) |
| Anti–PSGL-1 (moAb PL-2) | 99% (97) | 1% (10) | 96% (105) | 0% (25) |
Flow cytometric analysis and Western blot results (Figure5) showed the complete digestion of PSGL-1 polypeptide on both CLA+ and CLAlow T cells following bromelain treatment, and although HECA-452 expression on CLA+ T cells was markedly reduced, HECA-452 levels on CLAlow T cells were relatively unaffected by bromelain.